Alopecia totalis — the complete loss of scalp hair as a result of autoimmune alopecia areata — presents one of the most challenging questions in hair restoration: can a transplant restore what an autoimmune attack has destroyed?
The answer, for the majority of patients with active alopecia totalis, is that hair transplant surgery is not currently appropriate. The same autoimmune mechanism that caused the original hair loss will, in most cases, attack transplanted follicles just as it attacked the native ones. Grafts implanted into scalp affected by active alopecia totalis typically do not survive long-term.
The situation changes for patients who have experienced long-term, sustained remission — typically defined as at least two consecutive years without new activity and with confirmed stability on clinical assessment. In this small subset of patients, carefully planned FUE transplantation has shown some success in restoring partial coverage, with the understanding that the risk of recurrence remains.
The emergence of JAK inhibitors — particularly baricitinib and ritlecitinib — as effective treatments for moderate to severe alopecia areata has changed the landscape. These medications can induce regrowth in a significant proportion of alopecia totalis patients who were previously without effective treatment options. For patients in whom JAK inhibitor therapy achieves stable regrowth, the hair transplant question may become more relevant in the future.
Any patient with alopecia totalis considering hair transplant surgery should be under the care of a dermatologist specialising in hair disorders before approaching a hair transplant surgeon. The sequence of treatment matters enormously in this condition.
Related reading
